Prostate Cancer Cell Models for Research

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.4 million new cases and 375,000 deaths in 2020 (WHO GLOBOCAN). In the United States, the lifetime risk of developing prostate cancer is 1 in 8, and it is the most common non-skin cancer among American men (NCI). The 5-year survival rate for localized and regional prostate cancer is nearly 100%, but it drops to 30% for distant metastatic disease (NCI SEER). Key risk factors include age, family history, and genetic mutations such as BRCA1/2 and HOXB13. African American men have a higher incidence and mortality rate. The disease is highly heterogeneous, ranging from indolent to aggressive, necessitating robust research models.

Prostate cancer is an ideal model for studying hormone-driven carcinogenesis, tumor progression, and therapeutic resistance. The androgen receptor (AR) signaling pathway is central to disease biology, and targeting it has been a major therapeutic strategy. However, resistance to androgen deprivation therapy (ADT) remains a challenge. Research focuses on understanding AR mutations, splice variants, and cross-talk with other pathways. Public datasets such as TCGA and cBioPortal provide extensive genomic and transcriptomic data, enabling integrative analyses. Open questions include the role of the tumor microenvironment, neuroendocrine differentiation, and the molecular basis of racial disparities. Gene-edited cell models are essential for functional validation of these findings.

Prostate cancer development involves several key pathways:

• • Androgen receptor (AR) signaling: AR activation drives proliferation and survival. Androgen deprivation therapy is a primary treatment, but resistance often occurs via AR amplification, mutations, or splice variants (e.g., AR-V7).
• • PI3K/AKT pathway: PTEN loss is common, leading to hyperactivation of PI3K/AKT/mTOR signaling, promoting cell growth and survival.
• • MAPK/ERK pathway: Mutations in RAS or RAF are less frequent but can activate this pathway, contributing to proliferation.
• • DNA repair pathways: Mutations in BRCA1/2, ATM, and other homologous recombination repair genes are found in a subset of prostate cancers, leading to genomic instability and sensitivity to PARP inhibitors.
• • WNT/β-catenin pathway: Aberrant activation is implicated in progression and therapy resistance.

Data from TCGA (Cancer Genome Atlas Research Network, 2015) and COSMIC.

Key signaling networks in prostate cancer:

• • Androgen receptor (AR) signaling: Core axis involving AR, its coactivators (e.g., NCOA1/2), and downstream targets (e.g., KLK3, TMPRSS2). Crosstalk with PI3K/AKT and MAPK pathways.
• • PI3K/AKT/mTOR: PTEN loss leads to AKT activation, which phosphorylates downstream targets like mTOR and FOXO. Feedback loops with AR signaling.
• • MAPK/ERK: RAS/RAF/MEK/ERK cascade, often activated by growth factor receptors (EGFR, HER2).
• • WNT/β-catenin: β-catenin stabilization leads to TCF/LEF transcription, promoting proliferation and epithelial-mesenchymal transition (EMT).
• • DNA damage response: ATM/ATR and homologous recombination repair pathways are critical; defects lead to genomic instability and sensitivity to PARP inhibitors.

Organoids derived from patient tumors retain the genetic heterogeneity of the original tumor and are useful for drug testing and personalized medicine. They can be cultured long-term and are amenable to gene editing.

Animal models are essential for studying prostate cancer in vivo:

• • Patient-derived xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice. They preserve tumor heterogeneity and are used for drug efficacy testing.
• • Genetically engineered mouse models (GEMM): Transgenic mice with prostate-specific mutations (e.g., PB-Cre; Pten fl/fl) develop prostate cancer. They allow study of tumor initiation and progression.
• • Induced models: Use of carcinogens (e.g., testosterone plus estradiol) or orthotopic injection of cancer cells. These are quicker but less genetically defined.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts (KO) and knock-ins (KI). These models are invaluable for studying gene function and drug response. For example:

• • PTEN knockout in LNCaP cells: LNCaP already has PTEN loss, but additional knockout of other genes (e.g., TP53) can be generated.
• • AR-V7 knock-in: Introducing the AR-V7 splice variant into AR-negative cell lines (e.g., PC3) allows study of ligand-independent AR signaling.
• • TP53 knockout: In cell lines with wild-type TP53 (e.g., DU145 has mutant, but RWPE-1 is wild-type), knockout can be used to study p53 function.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing validated models with minimal effort. These models are typically generated using CRISPR-Cas9 technology and are quality-controlled for on-target editing and absence of off-target effects.

Gene-edited cell lines are used to validate the function of genes implicated in prostate cancer. For example:

• • Knockout of tumor suppressors (e.g., PTEN, TP53) in normal prostate epithelial cells (e.g., RWPE-1) can transform them into cancer-like cells, revealing their role in tumor suppression.
• • Knock-in of oncogenic mutations (e.g., AR T877A) into AR-negative cells can confer androgen responsiveness, enabling study of AR signaling.
• • CRISPR screens using pooled libraries can identify genes essential for cell survival or drug resistance.

Isogenic cell line pairs (e.g., parental vs. gene-edited) are powerful tools for drug screening:

• • Identify resistance mechanisms: For example, generating AR-V7 knock-in in LNCaP cells can model resistance to enzalutamide, allowing screening for drugs that target AR-V7.
• • Synthetic lethality: Knockout of DNA repair genes (e.g., BRCA2) makes cells sensitive to PARP inhibitors, providing a model for testing combination therapies.
• • High-throughput screening: Gene-edited cells can be used in 384-well plates to screen compound libraries, with readouts like cell viability or reporter gene expression.

Gene-edited cells facilitate the discovery of biomarkers:

• • CRISPR knockout of a gene of interest can be used to identify downstream effectors via transcriptomics or proteomics, revealing potential biomarkers.
• • Synthetic lethality screens can identify genes whose loss is lethal only in the context of a specific mutation, which can serve as therapeutic targets and biomarkers.
• • Reporter cell lines (e.g., GFP under an AR-responsive promoter) can be used to monitor pathway activity and screen for modulators.